13D Filing: OrbiMed Advisors and Pieris Pharmaceuticals Inc. (PIRS)

(c)

______________________

* The Shares were sold in a block order at a price of $8.98 (February 13, 2018).

Except as disclosed above and in Amendment No. 2, the Reporting Persons have not effected any transactions in the Shares during the past sixty (60) days.

(d) Not applicable.

(e) Not applicable.

Item 6.

Contracts, Arrangements, Understandings or Relationship with Respect to Securities of the Issuer

In addition to the relationships between the Reporting Persons described in Items 2 and 5 above, GP III is the sole general partner of OPI III, pursuant to the terms of the limited partnership agreement of OPI III. Advisors is the sole managing member of GP III, pursuant to the terms of the limited liability company agreement of GP III, and the sole general partner of Associates III, pursuant to the terms of the limited partnership agreement of Associates III. Pursuant to these agreements and relationships, Advisors and GP III have discretionary investment management authority with respect to the assets of OPI III, and Advisors has discretionary investment management authority with respect to the assets of Associates III. Such authority includes the power of GP III and Advisors to vote and otherwise dispose of securities purchased by OPI III, and the power of Advisors to vote and otherwise dispose of securities purchased by Associates III. The number of outstanding Shares held of record by OPI III is 5,500,730, and the number of outstanding Shares held of record by Associates III is 49,270. Advisors may be considered to hold indirectly 5,550,000 Shares, and GP III may be considered to hold indirectly 5,500,730 Shares.

Item 7.

Materials to Be Filed as Exhibits

Exhibit 1 – Joint Filing Agreement among OrbiMed Advisors LLC and OrbiMed Capital GP III LLC.

Seller	Date of Transaction	Transaction	Number of Shares	Price Per Share*
OPI III	February 13, 2018	Acquired upon the exercise of stock options	6,057	$4.68
Associates III	February 13, 2018	Acquired upon the exercise of stock options	58	$4.68
OPI III	February 13, 2018	Acquired upon the exercise of stock options	1,765	$5.08
Associates III	February 13, 2018	Acquired upon the exercise of stock options	17	$5.08
OPI III	February 13, 2018	Sold	7,822	$8.98
Associates III	February 13, 2018	Sold	75	$8.98

13D Filing: OrbiMed Advisors and Pieris Pharmaceuticals Inc. (PIRS)

Published on February 22, 2018 at 8:40 am by Insider Monkey Staff in Hedge Funds

Page 6 of 9 – SEC Filing

Follow Pieris Pharmaceuticals Inc. (NYSE:PIRS)

Follow Pieris Pharmaceuticals Inc. (NYSE:PIRS)

AI Fire Sale: Insider Monkey’s #1 AI Stock Pick Is On A Steep Discount

Published on October 30, 2024 at by Inan Dogan, PhD

A New Dawn is Coming to U.S. Stocks

Published on September 27, 2024 at by Insider Monkey Staff